Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F12%3A00009420" target="_blank" >RIV/00023736:_____/12:00009420 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.3892/etm.2011.363" target="_blank" >http://dx.doi.org/10.3892/etm.2011.363</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3892/etm.2011.363" target="_blank" >10.3892/etm.2011.363</a>

Result language
angličtina
Original language name
Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression
Original language description
Monitoring of WT1 expression by quantitative PCR in patients with AML has been shown as a suitable marker of minimal residual disease. The WT1 expression correlated with clinical outcome and as a border of molecular relapse was determined the upper remission limit of WT1 expression.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
<a href="/en/project/NS10632" target="_blank" >NS10632: New molecular markers for monitoring of residual disease in acute myeloid leukemia patients</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)